Search

Your search keyword '"Osella, Giangiacomo"' showing total 30 results
Start Over Author "Osella, Giangiacomo"
30 results on '"Osella, Giangiacomo"'

3. Adrenal Incidentalomas

Author

Terzolo, Massimo, Osella, Giangiacomo, Alì, Anna, Angeli, Alberto, Melmed, Shlomo, editor, and de Herder, Wouter W., editor

Published
2000
Full Text
View/download PDF

12. Dietary calcium intake in a cohort of individuals evaluated for low bone mineral density: a multicenter Italian study.

Author

Cairoli, Elisa, Aresta, Carmen, Giovanelli, Luca, Eller-Vainicher, Cristina, Migliaccio, Silvia, Giannini, Sandro, Giusti, Andrea, Marcocci, Claudio, Gonnelli, Stefano, Isaia, Gian Carlo, Rossini, Maurizio, Chiodini, Iacopo, Di Stefano, Marco, the Italian Society for Osteoporosis, Mineral Metabolism, Skeletal Diseases (SIOMMMS), Galmarini, Valter, Passeri, Giovanni, Di Salvo, Fabio, Osella, Giangiacomo, Tripodi, Francesco, and Valenti, Roberto

Abstract

Background: A low calcium intake is a well-known factor that influences the bone mineral density (BMD) maintenance. In the presence of inadequate calcium intake, secondary hyperparathyroidism develops, leading to an increased bone turnover and fracture risk. Aims: To assess the dietary calcium intake in relation with osteoporosis and fragility fracture in a cohort of Italian individuals evaluated for low BMD. Methods: A 7-day food-frequency questionnaire was administered to 1793 individuals, who were consecutively referred at the Centers of the Italian Society for Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS) for low BMD. Results: In 30.3% and 20.9% of subjects, the calcium intake was inadequate (< 700 mg/day) and adequate (> 1200 mg/day), respectively. As compared with patients with adequate calcium intake, those with inadequate calcium intake were younger (65.5 ± 10.8 vs 63.9 ± 11.5 years, p = 0.03) and they more frequently reported adverse reactions to food (3.2% vs 7.2% p = 0.01) and previous major fragility fractures (20.8% vs 27.0%, p = 0.03). Patients with calcium intake < 700 mg/day showed a higher prevalence of diabetes mellitus, idiopathic hypercalciuria and food allergy/intolerance (8.1%, 5.1%, 7.2%, respectively) than patients with calcium intake > 700 mg/day (5.3%, 3.0%, 4.1%, respectively, p < 0.04 for all comparisons), also after adjusting for age, gender and body mass index. In 30.3% of fractured subjects, the calcium intake was < 700 mg/day. Discussion: In Italy, a low calcium intake is highly prevalent in individuals at risk for low BMD. Importantly, an inadequate calcium intake is highly prevalent even in patients with history of fragility fractures. Conclusions: Only about a fifth of patients being assessed for low BMD in an Italian SIOMMMS referral Centre have an adequate calcium intake. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. A Survey on Adrenal Incidentaloma in Italy*

Author

Mantero, Franco, Terzolo, Massimo, Arnaldi, Giorgio, Osella, Giangiacomo, Masini, Anna Maria, Al`g, Anna, Giovagnetti, Marilena, Opocher, Giuseppe, and Angeli, Alberto

Published
2000

20. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation:Is Prompt Antiresorptive Therapy Always Recommended, Even When the Risk of Fracture Seems Low? A Case Report

Author

Osella, Giangiacomo, Puglisi, Soraya, Alì, Anna, Reimondo, Giuseppe, and Terzolo, Massimo

Abstract

Background: Non-osteoporotic patients with endocrine-sensitive breast cancer are oftentreated with denosumab only during the anti-aromatase treatment, and when the anti-aromatasetherapy is discontinued, no antiresorptive drug is prescribed. This case report clearly shows howeven a patient with a low risk of fractures could have multiple rebound vertebral fractures afterdenosumab discontinuation. Case Presentation: We report the case of a 60-year-old woman who suffered from multiple vertebralfractures only seven months after discontinuation of denosumab that had been administered toprevent bone loss related to three years of aromatase inhibitors as adjuvant therapy for breast cancer.No antiresorptive therapy was prescribed at the time of denosumab discontinuation, assumingthat the patient had a low absolute risk of fracture after the withdrawal of the aromatase inhibitor. Conclusion: This case underlines the relative irrelevance of bone mineral density and clinical algorithmsin predicting the risk of rebound-associated vertebral fractures after denosumab discontinuationand the strong recommendation to always switch to another antiresorptive therapy (such aszoledronic acid) immediately at the time of denosumab discontinuation.

Published
2021
Full Text
View/download PDF

21. Novel mutation of PPOXgene in a patient with abdominal pain and syndrome of inappropriate antidiuresis

Author

Tabaro, Isabella, Reimondo, Giuseppe, Osella, Giangiacomo, Aurizi, Caterina, Caraci, Pasquale, Barbieri, Luca, Giachino, Daniela, Sirchia, Fabio, and Terzolo, Massimo

Abstract

Acute porphyrias are metabolic disorders of heme biosynthesis characterized by acute life-threatening attacks. The diagnosis is often missed since clinical presentation is aspecific mimicking other medical and surgical conditions. Variegate porphyria (VP) is an autosomal dominant inherited disease with incomplete penetrance due to decreased activity of the Protoporphyrinogen Oxydase (PPOX) gene; most VP mutations are family specific. We report the case of a 40 year-old woman who presented many times to the emergency department complaining of unexplained abdominal pain and laboratory investigations showed repeatedly hyponatremia. Syndrome of inappropriate antidiuresis (SIAD) was confirmed and measurement of urine porphobilinogen and delta-aminolevulinic acid disclosed the diagnosis of acute porphyria. The genetic analysis of PPOX gene was performed. The entire coding sequence and exon/intron boundaries of PPOX gene were amplified in 5 different Polymerase Chain Reaction (PCR) fragments. In silico prediction of the pathogenicity of the mutation was determined by using different tools, Polyphen2, SNPs&GO, SNPs3D. The genetic analysis of PPOX gene revealed a novel missense variant c.1376 G > A (p.Cys459Tyr) in heterozygous state. The same variant was later found in one of her cousins with skin lesions and other three younger asymptomatic relatives. We provided evidence that this novel mutation is likely to be pathogenetic. Our case highlights the importance of considering VP in the differential diagnosis of SIAD and underlines the role of genetic screening in the management of such patients. The finding of a novel mutation of PPOX gene in our index case has allowed to recognize an affected family.

Published
2018
Full Text
View/download PDF

22. Subclinical Cushing's syndrome

Author

Terzolo, Massimo, primary, Bovio, Silvia, additional, Pia, Anna, additional, Osella, Giangiacomo, additional, Borretta, Giorgio, additional, Angeli, Alberto, additional, and Reimondo, Giuseppe, additional

Published
2007
Full Text
View/download PDF

24. Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal nonosteoporotic women in the early postmenopausal period.

Author

Osella, Giangiacomo, Ventura, Massimo, Ardito, Arianna, Allasino, Barbara, Termine, Angela, Saba, Laura, Vitetta, Rosetta, Terzolo, Massimo, and Angeli, Alberto

Subjects
*HYDROCORTISONE, *OSTEOPOROSIS in women, *POSTMENOPAUSE, *BONE density, *DUAL-energy X-ray absorptiometry, *LONGITUDINAL method, *CROSS-sectional method
Abstract

Objective: The aim of the study was to evaluate the relationship between cortisol secretion, bone health, and bone loss in a cohort of normal women in the early postmenopausal period. Methods: We measured lumbar and hip bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) and heel ultrasound parameters in 82 healthy, nonosteoporotic (lumbar Tscore R≥2.0) women (median age 52.5 years, range 42-61). These women were examined in two sessions, 1 year apart, in the early postmenopausal period (onset of menopause between 6 and 60 months). Parameters of the hypothalamic-pituitary-adrenal (HPA) axis function were morning serum cortisol, morning and midnight salivary cortisol, 24-h urinary free cortisol (UFC), serum cortisol after 0.5 and 1 mg overnight dexamethasone, and DHEA-S. Results: In multiple regression analyses, the following significant inverse correlations were found: i) lumbar BMD and either 24-h UFC (P<0.005) or morning serum cortisol (P<0.05), ii) total femur and femoral neck BMD with morning serum cortisol (P=0.05 and P<0.05), and iii) heel ultrasound stiffness index and midnight salivary cortisol (P<0.005). The annual rate of change in lumbar and femoral BMD did not correlate with any of the above-mentioned hormonal variables. No difference was found in the parameters of HPA axis function in slow (loss of BMD <1%) vs fast (loss of BMD ≥3%) bone losers. Conclusions: HPA axis may contribute to postmenopausal bone health, but differences in cortisol secretion do not influence the differential rate of bone loss between slow and fast bone losers in the early postmenopausal period, at least in healthy women. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

27. The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

Author

Window, Trova@UniTO(opens in a. new, Export, Download | Add to List | More,, Rheumatology, Clinical, Experimental, Volume 34, Issue 2, The Italian observational study on severe osteoporosis: 24 month results on incidence of fractures, adherence to treatment Idolazzi, L. Abb, Maugeri, D. B, Monti, S. C, Massarotti, M. D, Osella, G. E, Barbagallo, M. F, Del Fiacco, R. G, Silvestri, S. G, Adami, S. H, Altomonte, L. I, Bardoscia, A. J, Bertoldo, F. K, Bevilacqua, M. L, Bianchi, G. M, Brancati, A. N, Cagnoni, C. O, Cantatore, F. P. P, Capone, A. Q, Costanzo, G. R, D'Avola, G. S, De Giorgi, G. T, Di Matteo, L. U, Di Munno, O. V, Filipponi, P. W, Frisina, N. X, Fusco, A. Y, Giannini, S. Z, Guiducci, S. Aa, Iolascon, G. Ab, Isaia, Giovanni Carlo, Lombardi, G. Ad, Malavolta, N. Ae, Marcocci, C. Af, Migliaccio, S. Ag, Migliore, A. Ah, Muratore, M. Ai, Nardi, A. Aj, Ortolani, S. Ak, Pasquali, R. Al, Petto, H. Am, Pietrogrande, L. An, Pola, E. Ao, Previti, B. Ap, Resmini, G. Aq, Rubinacci, A. Ar, Russo, E. As, Scillitani, A. At, Silveri, F. Au, Leali, P. T. Av, Trotta, F. Aw, Ulivieri, M. Ax, Verdoia, C. Ay, Versace, F. Az, Vinicola, V. Ba, Idolazzi, Luca, Maugeri, Domenico, Monti, Salvatore, Massarotti, Marco, Osella, Giangiacomo, Barbagallo, Mario, Del Fiacco, Romano, Silvestri, Sandra, Adami, S, Altomonte, L, Barbagallo, M, Bardoscia, A, delle Murge, C, Bertoldo, F, Bevilacqua, M, Bianchi, G, Brancati, A, Cagnoni, C, Cantatore, Fp, Capone, A, DI COSTANZO, Gennaro, D'Avola, G, De Giorgi, G, Di Matteo, L, Di Munno, O, Filipponi, P, Frisina, N, Fusco, A, Giannini, S, Guiducci, S, Iolascon, G, Isaia, G, Lombardi, G, Malavolta, N, Marcocci, C, Migliaccio, S, Migliore, A, Muratore, M, Nardi, A, Ortolani, S, Osella, G, Pasquali, R, Petto, H, Pietrogrande, L, Pola, E, Previti, B, Resmini, G, Rubinacci, A, Russo, Pina Elvira, Scillitani, A, Silveri, F, Leali, Pt, Trotta, F, Ulivieri, M, Verdoia, C, Versace, F, and Vinicola, V.

Subjects
Aged, 80 and over, Male, Spinal fracture, Incidence, Osteoporosi, Middle Aged, Parathyroid hormone, Spine, Medication Adherence, Fracture, Observational study, Osteoporosis therapy, Teriparatide, 80 and over, Settore MED/33 - Malattie Apparato Locomotore, Humans, Osteoporosis, Female, Prospective Studies, Aged, Osteoporotic Fractures
Abstract

Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study. Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.

Published
2016

28. The Italian observational study on severe osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

Author

Idolazzi, L., Maugeri, D., Monti, S., Massarotti, M., Osella, G., Barbagallo, M., Del Fiacco, R., Silvestri, S., Adami, S., Altomonte, L., Bardoscia, A., Bertoldo, F., Bevilacqua, M., Bianchi, G., Brancati, A., Cagnoni, C., Cantatore, F. P., Capone, A., Costanzo, G., D Avola, G., Giorgi, G., Di Matteo, L., Di Munno, O., Filipponi, P., Frisina, N., Fusco, A., Giannini, S., Guiducci, S., Iolascon, G., Isaia, G., Lombardi, G., Malavolta, N., Marcocci, C., Migliaccio, S., Migliore, A., Muratore, M., Nardi, A., Ortolani, S., Pasquali, R., Petto, H., Pietrogrande, L., Pola, E., Previti, B., Resmini, G., Alessandro Rubinacci, Russo, E., Scillitani, A., Silveri, F., Leali, P. T., Trotta, F., Ulivieri, M., Verdoia, C., Versace, F., Vinicola, V., Idolazzi, Luca, Maugeri, Domenico, Monti, Salvatore, Massarotti, Marco, Osella, Giangiacomo, Barbagallo, Mario, Del Fiacco, Romano, Silvestri, Sandra, Adami, Silvano, Altomonte, Lorenzo, Bardoscia, Alfredo, Bertoldo, Francesco, Bevilacqua, Maurizio, Bianchi, Gerolamo, Brancati, Annamaria, Cagnoni, Carlo, Cantatore, Francesco Paolo, Capone, Antonio, Costanzo, Giuseppe, D'Avola, Giovanni, De Giorgi, Giuseppe, Di Matteo, Luigi, Di Munno, Ombretta, Filipponi, Paolo, Frisina, Nicola, Fusco, Alessandra, Giannini, Sandro, Guiducci, Serena, Iolascon, Giovanni, Isaia, Giancarlo, Lombardi, Gaetano, Malavolta, Nazzarena, Marcocci, Claudio, Migliaccio, Silvia, Migliore, Alberto, Muratore, Maurizio, Nardi, Alfredo, Ortolani, Sergio, Pasquali, Renato, Petto, Helmut, Pietrogrande, Luca, Pola, Enrico, Previti, Baldassarre, Resmini, Giuseppina, Rubinacci, Alessandro, Russo, Enzo, Scillitani, Alfredo, Silveri, Ferdinando, Leali, Paolo Tranquilli, Trotta, Francesco, Ulivieri, Massimo, Verdoia, Cesare, Versace, Francesco, and Vinicola, Vincenzo

Subjects
Spinal fracture, Fracture, Rheumatology, Observational study, Osteoporosis therapy, Teriparatide, Immunology, Osteoporosi, Immunology and Allergy, Parathyroid hormone, Spine
Abstract

Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: Incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.

29. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.

Author

Osella G, Puglisi S, Alì A, Reimondo G, and Terzolo M

Subjects
Bone Density, Denosumab adverse effects, Female, Humans, Middle Aged, Bone Density Conservation Agents adverse effects, Fractures, Bone, Osteoporosis, Postmenopausal complications, Osteoporosis, Postmenopausal drug therapy, Spinal Fractures diagnostic imaging, Spinal Fractures etiology
Abstract

Background: Non-osteoporotic patients with endocrine-sensitive breast cancer are often treated with denosumab only during the anti-aromatase treatment, and when the anti-aromatase therapy is discontinued, no antiresorptive drug is prescribed. This case report clearly shows how even a patient with a low risk of fractures could have multiple rebound vertebral fractures after denosumab discontinuation., Case Presentation: We report the case of a 60-year-old woman who suffered from multiple vertebral fractures only seven months after discontinuation of denosumab that had been administered to prevent bone loss related to three years of aromatase inhibitors as adjuvant therapy for breast cancer. No antiresorptive therapy was prescribed at the time of denosumab discontinuation, assuming that the patient had a low absolute risk of fracture after the withdrawal of the aromatase inhibitor., Conclusion: This case underlines the relative irrelevance of bone mineral density and clinical algorithms in predicting the risk of rebound-associated vertebral fractures after denosumab discontinuation and the strong recommendation to always switch to another antiresorptive therapy (such as zoledronic acid) immediately at the time of denosumab discontinuation., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Published
2021
Full Text
View/download PDF

30. The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment.

Author

Idolazzi L, Maugeri D, Monti S, Massarotti M, Osella G, Barbagallo M, Del Fiacco R, and Silvestri S

Subjects
Aged, Aged, 80 and over, Female, Humans, Incidence, Male, Middle Aged, Prospective Studies, Teriparatide therapeutic use, Medication Adherence, Osteoporosis drug therapy, Osteoporotic Fractures epidemiology
Abstract

Objectives: To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment., Methods: Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group., Results: Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period., Conclusions: In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results